CoChat

Engulfment of cerebral apoptotic bodies controls the course of prion disease in a mouse strain–dependent manner

Open access
Kranich, Jan, Krautler, Nike Julia, Falsig, Jeppe, Ballmer, Boris, Li, Shulei, Hutter, Gregor, Schwarz, Petra, Moos, Rita, Julius, Christian, Miele, Gino, Aguzzi, Adriano · 2010 · Journal of Experimental Medicine

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Progressive accumulation of PrPSc, a hallmark of prion diseases, occurs when conversion of PrPC into PrPSc is faster than PrPSc clearance. Engulfment of apoptotic bodies by phagocytes is mediated by Mfge8 (milk fat globule epidermal growth factor 8). In this study, we show that brain Mfge8 is primarily produced by astrocytes. Mfge8 ablation induced accelerated prion disease and reduced clearance of cerebellar apoptotic bodies in vivo, as well as excessive PrPSc accumulation and increased prion titers in prion-infected C57BL/6 × 129Sv mice and organotypic cerebellar slices derived therefrom. These phenotypes correlated with the presence of 129Sv genomic markers in hybrid mice and were not observed in inbred C57BL/6 Mfge8−/− mice, suggesting the existence of additional strain-specific genetic modifiers. Because Mfge8 receptors are expressed by microglia and depletion of microglia increases PrPSc accumulation in organotypic cerebellar slices, we conclude that engulfment of apoptotic bodies by microglia may be an important pathway of prion clearance controlled by astrocyte-borne Mfge8.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20092401

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Mfge8−/− mice show accelerated disease progression. (A) B6.129-Mfge8−/−, B6.129-Mfge8−/+, and B6.129-Mfge8+/+ were inoculated i.c. with 3 log LD50 (n = 10 for Mfge8−/−, n = 4 for Mfge8+/−, and n = 11 for Mfge8+/+) and i.p. with 3 log LD50 per group of RML6 prions. The mean incubation time after i.c. inoculation was significantly accelerated in Mfge8−/− mice (159 ± 2 d in Mfge8−/−, 179 ± 3 d in Mfge8+/−, and 202 ± 3.9 d in Mfge8+/+ mice; P < 0.0001, logrank). Differences in incubation time after i.p. inoculation were less pronounced (206 ± 6 d in Mfge8−/− and 229 ± 10 d in Mfge8+/+ mice) but still significant (P = 0.004, logrank test). (B) Stainings of brain sections after 30 dpi (left) or at terminal stage (right) using anti-PrP antibody SAF84. Bars, 1 mm. (C) Western blot of PK-digested brain homogenates from i.c. inoculated Mfge8+/+ and Mfge8−/− mice using anti-PrP antibody POM1 (C, uninoculated brain homogenate). Western blot for actin on non-PK–digested sample is shown below. Densitometric quantitation of POM1 signal normalized over actin expression. Bar graph shows mean relative signal intensity (n = 4; *, P = 0.03; Student’s t test). (D) MPA of brain homogenates from Mfge8+/+ and Mfge8−/− mice at 120 dpi or at terminal disease (n = 6–7 mice per group; *, P = 0.034; Student’s t test) indicated in percentages of RML6 prion–inoculated brain homogenate. Mfge8−/− mice sacrificed at 120 dpi showed a slight increase over Mfge8+/+ mice. (E) Mfge8+/+ and Mfge8−/− cerebellar slices were inoculated with 3 × 3 log LD50 RML6 prions or with noninfectious brain homogenate (mock), harvested after 5 wk, homogenized, and PK digested (C, brain homogenate from a terminal RML inoculated mouse used as positive control). PrPSc levels were analyzed by Western blotting using POM1 and normalized against actin (without PK digestion) by densitometry (bar graph; n = 4; *, P = 0.024; Student’s t test). Error bars represent SD. Histology, Western blot, and MPA results represent at least four independent experiments.
Figure 1. Mfge8−/− mice show accelerated disease progression. (A) B6.129-Mfge8−/−, B6.129-Mfge8−/+, and B6.129-Mfge8+/+ were inoculated i.c. with 3 log LD50 (n = 10 for Mfge8−/−, n = 4 for Mfge8+/−, and n = 11 for Mfge8+/+) and i.p. with 3 log LD50 per group of RML6 prions. The mean incubation time after i.c. inoculation was significantly accelerated in Mfge8−/− mice (159 ± 2 d in Mfge8−/−, 179 ± 3 d in Mfge8+/−, and 202 ± 3.9 d in Mfge8+/+ mice; P < 0.0001, logrank). Differences in incubation time after i.p. inoculation were less pronounced (206 ± 6 d in Mfge8−/− and 229 ± 10 d in Mfge8+/+ mice) but still significant (P = 0.004, logrank test). (B) Stainings of brain sections after 30 dpi (left) or at terminal stage (right) using anti-PrP antibody SAF84. Bars, 1 mm. (C) Western blot of PK-digested brain homogenates from i.c. inoculated Mfge8+/+ and Mfge8−/− mice using anti-PrP antibody POM1 (C, uninoculated brain homogenate). Western blot for actin on non-PK–digested sample is shown below. Densitometric quantitation of POM1 signal normalized over actin expression. Bar graph shows mean relative signal intensity (n = 4; *, P = 0.03; Student’s t test). (D) MPA of brain homogenates from Mfge8+/+ and Mfge8−/− mice at 120 dpi or at terminal disease (n = 6–7 mice per group; *, P = 0.034; Student’s t test) indicated in percentages of RML6 prion–inoculated brain homogenate. Mfge8−/− mice sacrificed at 120 dpi showed a slight increase over Mfge8+/+ mice. (E) Mfge8+/+ and Mfge8−/− cerebellar slices were inoculated with 3 × 3 log LD50 RML6 prions or with noninfectious brain homogenate (mock), harvested after 5 wk, homogenized, and PK digested (C, brain homogenate from a terminal RML inoculated mouse used as positive control). PrPSc levels were analyzed by Western blotting using POM1 and normalized against actin (without PK digestion) by densitometry (bar graph; n = 4; *, P = 0.024; Student’s t test). Error bars represent SD. Histology, Western blot, and MPA results represent at least four independent experiments.CC BY-NC-SA · PubMed Central
Figure 2. Histopathological analysis of terminal Mfge8−/− brains. (A) Astroglia proliferation was analyzed by GFAP staining. (B) Microglial activation was visualized by IBA1 staining. (C) TUNEL staining on cerebellar cryosection of i.c. inoculated B6.129-Mfge8−/− (n = 5) and B6.129-Mfge8+/+ mice (n = 7). Sections were counterstained with DAPI. Bar graph shows quantitation of TUNEL+ cells from at least three cerebellar areas per mouse. Number of TUNEL+ cells was normalized against the number of DAPI+ nuclei. Graph shows percentage of TUNEL+ cells per area ± SD (*, P = 0.023; Student’s t test). Results summarize at least five independent experiments. Bars: (A and C) 100 µm; (B) 200 µm.
Figure 2. Histopathological analysis of terminal Mfge8−/− brains. (A) Astroglia proliferation was analyzed by GFAP staining. (B) Microglial activation was visualized by IBA1 staining. (C) TUNEL staining on cerebellar cryosection of i.c. inoculated B6.129-Mfge8−/− (n = 5) and B6.129-Mfge8+/+ mice (n = 7). Sections were counterstained with DAPI. Bar graph shows quantitation of TUNEL+ cells from at least three cerebellar areas per mouse. Number of TUNEL+ cells was normalized against the number of DAPI+ nuclei. Graph shows percentage of TUNEL+ cells per area ± SD (*, P = 0.023; Student’s t test). Results summarize at least five independent experiments. Bars: (A and C) 100 µm; (B) 200 µm.CC BY-NC-SA · PubMed Central
Figure 3. Analysis of the cellular source of Mfge8. (A) ISH for Mfge8 on brain cryosections. Mfge8+ cells (dark purple) were found in cerebellar (top) and cortical areas (bottom). Low and high magnification photographs of the same cerebellar (top) and cortical (bottom) areas are shown. Boxes indicate areas shown in higher magnifications. The arrow indicates the cell shown in high magnification. (B) Expression of Mfge8 in cultured astrocytes, microglia, oligodendrocytes, and neurons was quantified by quantitative RT-PCR. Mfge8 expression in each subset relative to total brain is shown (n = 3). (C) ISH for Mfge8 in prion-inoculated Mfge8+/+ mice at terminal stage (left). Right panel shows relative Mfge8 mRNA expression in mock- and RML-inoculated brains as assessed by quantitative RT-PCR (n = 3). (D) Quantitative RT-PCR quantitation of Mfge8, Cd11b, and Gfap expression in cerebellar slice cultures from untreated CD11b-HSVTK mice (HSVTK), prion-inoculated untreated CD11b-HSVTK mice (HSVTK + RML), GCV-treated CD11b-HSVTK mice (HSVTK + GCV), and prion-inoculated GCV-treated CD11b-HSVTK mice (HSVTK + RML + GCV; Student’s t test; n = 4). Uninfected HSVTK + GCV slices compared with HSVTK slices have a slight but significant reduction of Mfge8 (***, P = 0.0007). No difference in expression in HSVTK + RML + GCV slices compared with HSVTK + RML slices (NS, P = 0.1566). HSVTK + RML slices compared with HSVTK show significant down-regulation (**, P = 0.0082). CD11b expression is down-regulated by almost 3 logs in GCV -treated slices, confirming efficient depletion of microglia (HSVTK + GCV: ***, P < 0.0001; HSVTK + RML + GCV: ***, P < 0.0001). Gfap expression is slightly reduced after GC treatment (HSVTK + GCV: *, P = 0.0255). (E) Analysis of integrin αv (Itgav), β3 (Itgb3), and β5 (Itgb5) expression by quantitative RT-PCR (Student’s t test; n = 4). No significant changes in Itgav expression were found. Itgb3 and Itgb5 were down-regulated in GCV-treated compared with nontreated slices (Itgb3 HSVTK + GCV: ***, P < 0.0001; Itgb3 HSVTK + RML + GCV: ***, P = 0.0007; Itgb5 HSVTK + GCV: ***, P = 0.0002; Itgb5 HSVTK + RML + GCV: ***, P < 0.0001). Error bars represent SD. ISH and quantitative RT-PCR results are shown representative of 3 and 12 independent experiments, respectively.
Figure 3. Analysis of the cellular source of Mfge8. (A) ISH for Mfge8 on brain cryosections. Mfge8+ cells (dark purple) were found in cerebellar (top) and cortical areas (bottom). Low and high magnification photographs of the same cerebellar (top) and cortical (bottom) areas are shown. Boxes indicate areas shown in higher magnifications. The arrow indicates the cell shown in high magnification. (B) Expression of Mfge8 in cultured astrocytes, microglia, oligodendrocytes, and neurons was quantified by quantitative RT-PCR. Mfge8 expression in each subset relative to total brain is shown (n = 3). (C) ISH for Mfge8 in prion-inoculated Mfge8+/+ mice at terminal stage (left). Right panel shows relative Mfge8 mRNA expression in mock- and RML-inoculated brains as assessed by quantitative RT-PCR (n = 3). (D) Quantitative RT-PCR quantitation of Mfge8, Cd11b, and Gfap expression in cerebellar slice cultures from untreated CD11b-HSVTK mice (HSVTK), prion-inoculated untreated CD11b-HSVTK mice (HSVTK + RML), GCV-treated CD11b-HSVTK mice (HSVTK + GCV), and prion-inoculated GCV-treated CD11b-HSVTK mice (HSVTK + RML + GCV; Student’s t test; n = 4). Uninfected HSVTK + GCV slices compared with HSVTK slices have a slight but significant reduction of Mfge8 (***, P = 0.0007). No difference in expression in HSVTK + RML + GCV slices compared with HSVTK + RML slices (NS, P = 0.1566). HSVTK + RML slices compared with HSVTK show significant down-regulation (**, P = 0.0082). CD11b expression is down-regulated by almost 3 logs in GCV -treated slices, confirming efficient depletion of microglia (HSVTK + GCV: ***, P < 0.0001; HSVTK + RML + GCV: ***, P < 0.0001). Gfap expression is slightly reduced after GC treatment (HSVTK + GCV: *, P = 0.0255). (E) Analysis of integrin αv (Itgav), β3 (Itgb3), and β5 (Itgb5) expression by quantitative RT-PCR (Student’s t test; n = 4). No significant changes in Itgav expression were found. Itgb3 and Itgb5 were down-regulated in GCV-treated compared with nontreated slices (Itgb3 HSVTK + GCV: ***, P < 0.0001; Itgb3 HSVTK + RML + GCV: ***, P = 0.0007; Itgb5 HSVTK + GCV: ***, P = 0.0002; Itgb5 HSVTK + RML + GCV: ***, P < 0.0001). Error bars represent SD. ISH and quantitative RT-PCR results are shown representative of 3 and 12 independent experiments, respectively.CC BY-NC-SA · PubMed Central
Figure 4. Inoculation of Mfge8−/− mice on different genetic backgrounds. (A) Mfge8+/+, Mfge8+/−, and Mfge8−/− mice on B6.129 (top), C57BL/6 (middle), and B6.129.Balb/C (bottom) background were inoculated i.c. with 3 log LD50 of RML5 prions (n = 5–9 per group). Significantly accelerated incubation times between Mfge8−/− and Mfge8+/+ or Mfge8+/− mice were only seen in B6.129 and B6.129.Balb/C backgrounds (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Right panel summarizes the STR analysis of inoculated mice. Pie charts show the percentage of B6 (blue), Balb/C (green), and 129Sv (red) alleles per mouse. Each chart represents one mouse. Only alleles that could unambiguously be assigned to one of the three different genetic backgrounds are represented in the pie charts. (B) Linear regression analysis comparing incubation time with number of 129Sv alleles. No correlation was seen between incubation time and number of 129Sv alleles in Mfge8+/+ and Mfge8+/− mice. However, there was a strong correlation in Mfge8−/− mice. Results represent at least five independent experiments.
Figure 4. Inoculation of Mfge8−/− mice on different genetic backgrounds. (A) Mfge8+/+, Mfge8+/−, and Mfge8−/− mice on B6.129 (top), C57BL/6 (middle), and B6.129.Balb/C (bottom) background were inoculated i.c. with 3 log LD50 of RML5 prions (n = 5–9 per group). Significantly accelerated incubation times between Mfge8−/− and Mfge8+/+ or Mfge8+/− mice were only seen in B6.129 and B6.129.Balb/C backgrounds (*, P < 0.05; **, P < 0.01; ***, P < 0.001). Right panel summarizes the STR analysis of inoculated mice. Pie charts show the percentage of B6 (blue), Balb/C (green), and 129Sv (red) alleles per mouse. Each chart represents one mouse. Only alleles that could unambiguously be assigned to one of the three different genetic backgrounds are represented in the pie charts. (B) Linear regression analysis comparing incubation time with number of 129Sv alleles. No correlation was seen between incubation time and number of 129Sv alleles in Mfge8+/+ and Mfge8+/− mice. However, there was a strong correlation in Mfge8−/− mice. Results represent at least five independent experiments.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 114

Metadata

Authors
Kranich, J., Krautler, N. J., Falsig, J., Ballmer, B., Li, S., Hutter, G., Schwarz, P., Moos, R., Julius, C., Miele, G., & Aguzzi, A.
Affiliations
  • University Hospital Zurich (CH)
  • Institute of Neuropathology, University Hospital of Zurich, 8091 Zurich, Switzerland
Corresponding author
Aguzzi, Adriano
Venue
Journal of Experimental Medicine
Published
2010-09-13
Volume
207
Issue
10
Pages
2271-2281
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2120168709
Cited by
110
References
40
Citations by year
2026: 1 · 2025: 4 · 2024: 7 · 2023: 1 · 2022: 5 · 2021: 12 · 2020: 6 · 2019: 10 · 2018: 9 · 2017: 8 · 2016: 8 · 2015: 4 · 2014: 8 · 2013: 11 · 2012: 10
FWCI
3.52
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
Funders
  • National Science Foundation
  • European Commission
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Prion Diseases and Protein Misfolding
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords
prion disease, MFG-E8, apoptotic bodies, phagocytosis, microglia, astrocytes, prion clearance, mouse strain differences
MeSH terms
Animals, Antigens, Surface, Astrocytes, Brain, Mice, Inbred C57BL, Milk Proteins, Species Specificity, Prion Diseases, Apoptosis, Microglia, PrPSc Proteins, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Engulfment of cerebral apoptotic bodies controls the course of prion disease in a mouse strain–dependent manner. https://app.cochat.ai/papers/10.1084/jem.20092401
The paper
Kranich, J., Krautler, N. J., Falsig, J., Ballmer, B., Li, S., Hutter, G., Schwarz, P., Moos, R., Julius, C., Miele, G., & Aguzzi, A. (2010). Engulfment of cerebral apoptotic bodies controls the course of prion disease in a mouse strain–dependent manner. Journal of Experimental Medicine. https://doi.org/10.1084/jem.20092401

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.